Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry
Authors' conclusion
Among individuals with hypertension, aRH that develops prior to mid-life is associated with substantially elevated cardiorenal disease risk across the lifespan.
Study context
- Population
- Individuals with hypertension prescribed ≥1 antihypertensive, FinnGen Study (Finland)
- Participants
- 48,721 individuals
- Exposure
- aRH vs 1 antihypertensive class
- aRHn = 5,715
- Outcome
- Cardiorenal outcomes
- Follow-up
- Across the lifespan
Methodological detailsnational registry, multivariable-adjusted Cox models
- National registry
- Multivariable-adjusted Cox models
Main finding
As reported in the abstract
lifetime
aRH
11.7%
5715
aRH vs One classHazard ratio (95% CI)
Renal failure
2.30(2.00–2.65)
Intracranial haemorrhage
1.50(1.08–2.05)
HF
1.40(1.24–1.63)
Cardiac death
1.79(1.45–2.21)
All-cause death
1.76(1.52–2.04)
Observational data: associations, not effects.
Original publication
Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry. Eur J Prev Cardiol. Published 2 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →